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Abstract
Introduction: Respiratory syncytial virus (RSV) is a major cause of hospital admission 
for acute lower respiratory tract infection in young children.
Objectives: We aimed to identify risk factors for hospitalized RSV disease and its 
severe outcomes.
Methods: We conducted a retrospective cohort study analyzing data of a ICD-10-
code-based hospital surveillance for severe acute respiratory infections (SARI). Using 
univariable and multivariable logistic regression analysis, we assessed age-group, 
gender, season, and underlying medical conditions as possible risk factors for RSV 
and its severe outcomes including ICU admission, application of ventilator support, 
and death, respectively.
Results: Of the 413 552 patients hospitalized with SARI in the database, 8761 were 
diagnosed with RSV from week 01/2009 to 20/2018 with 97% (8521) aged <5 years. 
Among children aged <5 years, age-groups 0-5 months (OR: 20.29, 95% CI: 18.37-
22.41) and 6 months-1 year (OR: 4.59, 95% CI: 4.16-5.06), and underlying respiratory 
and cardiovascular disorders specific to the perinatal period (OR: 1.32, 95% CI: 1.11-
1.57) were risk factors for being diagnosed with RSV. Age-group 0-5 months (OR: 
2.39, 95% CI: 1.45-3.94), low birth weight (OR: 6.77, 95% CI: 1.28-35.71), preterm 
newborn (OR: 6.71, 95% CI: 2.19-20.61), underlying respiratory and cardiovascular 
disorders specific to the perinatal period (OR: 4.97, 95% CI: 3.36-7.34), congenital 
malformation of the heart (OR: 3.65, 95% CI: 1.90-7.02), congenital malformation of 
the great vessels (OR: 3.50, 95% CI: 1.10-11.18), congenital defect originating in peri-
natal period (OR: 4.07, 95% CI: 1.71-9.70), cardiovascular disease (OR: 5.19, 95% CI: 
2.77-9.72), neurological disorders (OR: 6.48, 95% CI: 3.76-11.18), blood disease (OR: 
3.67, 95% CI: 1.98-6.79), and liver disease (OR: 14.99, 95% CI: 1.49-150.82) contrib-
uted to ICU admission in RSV cases.
Conclusions: Using ICD-10-based surveillance data allows to identify risk factors for 
hospitalized RSV disease and its severe outcomes, and quantify the risk in different 
age-groups.
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1  | INTRODUC TION
Respiratory syncytial virus (RSV) is a worldwide distributed patho-
gen of acute respiratory infection (ARI) of all ages. In infants and 
young children, RSV is the most common cause of acute lower respi-
ratory tract infection (ALRI) and a major cause of hospital admission 
for ALRI. Worldwide, about 33 million RSV-associated ALRI episodes 
occurred in children younger than 5 years, and about 3 million were 
severe enough to necessitate hospital admission in 2015.1,2 RSV has 
been found to be an important cause of viral infection requiring pe-
diatric intensive care unit (ICU) admission and ventilator support, as 
well as a frequent course of death in young children.3,4
Currently, there are no licensed vaccines against RSV; only 
passive immunization with palivizumab is available for young chil-
dren at high risk.5 In 2015, the World Health Organization Product 
Development for Vaccines Advisory Committee highlighted the 
development of RSV vaccines. Several novel RSV vaccines and 
long-acting monoclonal antibodies have shown promising results in 
clinical trials and are expected to enter the market in a short-medium 
term.6,7
Risk groups of severe RSV will benefit most from the RSV immu-
nization once RSV vaccines become available. So far, some studies 
indicated that besides some socio-demographic and environmental 
factors including being male, household crowding, and passive smok-
ing, underlying medical conditions such as prematurity, congenital 
heart disease, and chronic pulmonary and cardiovascular diseases 
were associated with RSV disease.8-10 Furthermore, certain under-
lying medical conditions predispose young children to severe RSV 
disease9,11 which is likely to result in ICU admission with ventilator 
support and a higher risk of death.12 However, to our knowledge, the 
risk of underlying medical conditions has not been assessed compre-
hensively with respect to risk for RSV and its severe outcomes, and 
studies have shown inconsistent results for some underlying medical 
conditions.10
The development of RSV vaccination strategies and the evalu-
ation of the effects of RSV vaccination in the future rely on timely 
epidemiological data and long-term observation of epidemiological 
situation of severe RSV and risk factors for severe RSV through 
national and other large-scale RSV surveillance systems. The 
Robert Koch Institute (RKI) established an International Statistical 
Classification of Diseases, 10th revision (ICD-10)-code-based sur-
veillance system for severe ARI (ICOSARI) in cooperation with a 
private hospital network in Germany in 2015. Data of respiratory 
hospitalizations have been collected through the ICOSARI.13,14
The aim of the present study was to identify risk factors, in par-
ticular underlying medical conditions as risk factors, for hospitalized 
RSV disease and its severe outcomes based on the ICD-10-code-
based surveillance data.
1.1 | Methods
We performed a retrospective cohort study based on secondary 
data analysis of the ICOSARI database. The hospital network of 
ICOSARI includes 45 original sentinel hospitals, and additional 
42 hospitals joined the hospital network after 2013. In 2015, 
84 sentinel hospitals of ICOSARI located in 13 of the 16 federal 
states of Germany, covered 4.3% hospitals, and accounted for 
5.9% of hospitalized patients in Germany. Since 2015, digital data 
of hospitalizations with any of respiratory ICD-10 code (chapter 
X: J00-J99)15 as primary or secondary discharge diagnosis have 
been collected prospectively and updated weekly. For retrospec-
tive analysis, ICD-10 datasets of ICOSARI for the years 2009 to 
2014 were collected. The collected data contain information on 
age, gender, admission and discharge date, primary and all second-
ary ICD-10 code discharge diagnoses, length of hospital and ICU 
stay (in days), length of ventilation (in hours), and discharge mode. 
Further detailed description of the ICOSARI methodology was 
published elsewhere.13
The ICOSARI system was approved by the RKI and HELIOS 
Kliniken GmbH data protection authorities. As ICOSARI involved no 
interventions and the analysis was based on anonymized data only, 
no ethical clearance was required for this study.13
We used the following case definitions:
• Severe ARI (SARI) case: any patient hospitalized with any of the 
ARI ICD-10 codes J09-J22 (J09-J11: influenza, J12-J18: pneumo-
nia, J20: acute bronchitis, J21: acute bronchiolitis, J22: unspec-
ified acute lower respiratory infection) as primary or secondary 
discharge diagnosis13,15; If a patient was readmitted to hospital, 
the patient would be counted again.
• RSV case: SARI case diagnosed with any of the RSV-specific ICD-
10 codes (J12.1: RSV pneumonia, J20.5: acute bronchitis due to 
RSV, J21.0: acute bronchiolitis due to RSV) as primary or second-
ary discharge diagnosis.15
• ICU-admitted RSV case: RSV case ever admitted to an ICU during 
the hospital stay.
• Ventilated RSV case: ICU-admitted RSV case ever required venti-
lator support during the hospital stay.
• Deceased RSV case: RSV case died in hospital.
ICU admission, application of ventilator support, and death 
were considered markers of severe outcomes of hospitalized RSV 
disease.
Due to the possible inconsistent recording practices on ICU ad-
mission and application of ventilator support in the sentinel hospitals 
(personal communication), data on ICU admission and application of 
ventilator support from the original sentinel hospitals before 2013 
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and from the additional sentinel hospitals before 2015 were ex-
cluded from our data evaluation.
The underlying medical conditions evaluated in our study were 
neonatal disorders (disorder of newborn related to slow fetal growth 
and fetal malnutrition), extremely low birth weight (<1000 g), low birth 
weight (1000-2499 g), extreme immaturity of newborn (<28 weeks), 
preterm newborn (28-37 weeks), respiratory and cardiovascular dis-
order specific to the perinatal period (eg, intrauterine hypoxia, birth 
asphyxia, respiratory distress of newborn, congenital pneumonia, 
neonatal aspiration syndromes, interstitial emphysema, pulmonary 
hemorrhage), congenital disorders (congenital malformation of the 
heart, congenital malformation of the great vessels, congenital defect 
originating in perinatal period, Down syndrome, sickle-cell disorder, 
cystic fibrosis), other comorbidities (vitamin D deficiency, asthma, 
chronic obstructive pulmonary disease (COPD), chronic pulmonary 
disease (excl. asthma and COPD), diabetes, cardiovascular disease, 
neurological disorders, blood disease (eg, nutritional anemias, coag-
ulation defects, purpura, and other hemorrhagic conditions), renal 
failure, liver disease, tuberculosis, cancer, HIV/AIDS), and pregnancy. 
The underlying medical conditions could be primary or secondary 
discharge diagnoses. The specific ICD-10 codes of the medical condi-
tions chosen for our data evaluation are listed in Table 1, which were 
adapted from the Elixhauser and Fleming Comorbidity Indices.16,17
For descriptive data analysis, we described the number of total 
RSV cases, ICU-admitted RSV cases, ventilated RSV cases, and 
deceased RSV cases by age-group (0-5 months, 6 months-1 year, 
2-4 years, 5-64 years, ≥65 years), gender, calendar week, and under-
lying medical condition, respectively. The mean and median length 
of hospital stay, ICU stay and ventilation, and discharge mode were 
investigated, respectively.
We carried out univariable and multivariable logistic regression 
analyses to assess age-group, gender, season, and underlying medi-
cal conditions as possible risk factors for being diagnosed with RSV 
among SARI cases, for ICU admission, application of ventilator sup-
port, and death among RSV cases, respectively. The univariable and 
multivariable logistic regression analyses were stratified in two age-
groups <5 years and ≥5 years. Underlying neonatal disorders were only 
evaluated as possible risk factors in the age-group <5 years. Normally, 
relative risk (RR) should be calculated to measure the association be-
tween the exposure and the outcome in a cohort study. However, the 
odds ratios (OR) provides a reasonable approximation of the RR if the 
outcome is rare and occurs in less than 10% of the unexposed popu-
lation.18 Our data met this condition that RSV cases were rare among 
SARI cases and RSV cases with different severe outcomes were rare 
among total RSV cases. Therefore, the ORs could be interpreted as RRs 
in our cohort study. ORs were calculated and presented with 95% con-
fidence interval (95% CI). Two-sided tests were applied. A P value of 
<.05 was considered statistically significant. Only variables indicating 
significant associations with RSV or any markers of severe outcomes of 
RSV in univariable logistic regression models were kept in multivariable 
logistic regression models, respectively.
We used Stata (version 15) and Microsoft Excel 2010 for the data 
analyses.
2  | RESULTS
2.1 | Study population (SARI cases)
A total of 413 552 SARI cases were identified from week 01/2009 
to 20/2018. More than half (232 340, 56%) of them were male, and 
64% (263 133) were ≥65 years old (Figures 1 and 2; Table 2). Of the 
SARI cases, 46% (188 948) received ARI (J09-J22) as primary dis-
charge diagnosis.
2.2 | RSV cases
A total of 8761 (2%) RSV cases were identified. More than half 
(4955, 57%) of them were male. Most RSV cases were children 
aged <5 years (8521, 97%). The mean and median length of hos-
pital stay were 6 and 5 days, respectively. Most (8599, 98%) RSV 
cases were discharged home, 2% (136) transferred to other facili-
ties, and 0.3% (25) died in hospital. Of the RSV cases, 8228 (94%) 
received RSV-specific ICD-10 codes as primary discharge diagno-
sis (J12.1: 2995, 36%; J20.5: 2089, 25%; J21.0: 3144, 38%). Of the 
total RSV cases, 6773 were from the original sentinel hospitals 
after 2013 or from the additional sentinel hospitals after 2015 
(Figures 1 and 2; Tables 2 and 3).
2.3 | ICU-admitted RSV cases
Of the total RSV cases, 492 (7%) ICU-admitted RSV cases were iden-
tified. More than half (262, 53%) of them were male, and 89% (438) 
were aged <5 years. The mean and median length of ICU stay were 
9 and 5 days, respectively. During the ICU stay, 38% (185) required 
ventilator support. Most (449, 91%) ICU-admitted RSV cases were 
discharged home, 6% (28) transferred to other facilities, and 3% (15) 
died in hospital (Figure 2; Table 3).
2.4 | Ventilated RSV cases
Of the 185 ventilated RSV cases, more than half (101, 55%) were 
male, and 81% (149) were aged <5 years. The mean and median 
ventilation length were 211 and 112 hours, respectively. Most 
(152, 82%) ventilated RSV cases were discharged home, 10% 
(18) transferred to other facilities, and 8% (15) died in hospital 
(Figure 2; Table 3).
2.5 | Deceased RSV cases
Of the 25 deceased RSV cases, more than half (16, 64%) were fe-
male, and nearly half (12, 48%) were ≥65 years old (Table 3). The 
mean and median length of hospital stay were 27 and 10 days, 
respectively.
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2.6 | RSV cases by calendar week
An overview of the number of total RSV cases and RSV cases with 
severe outcomes by calendar week is shown from week 01/2015 
to 20/2018. During the study period, the most severe season was 
2016/17 (Figure 3).
2.7 | RSV cases with underlying medical conditions
The proportion of total RSV cases with different underlying medical 
conditions varied from 0% to 3.5%. Respiratory and cardiovascular 
disorder specific to the perinatal period (282, 3.5%) and cardiovas-
cular disease (222, 2.5%) were the most common underlying medi-
cal conditions. They both were also the most common underlying 
medical conditions in the ICU-admitted (60, 12.7%; 69, 14.0%) and 
ventilated RSV cases (35, 19.0%; 47, 25.4%). Cardiovascular disease 
(15, 60.0%) and blood disease (9, 36.0%) were the most common un-
derlying medical conditions in deceased RSV cases. RSV cases with 
underlying sickle-cell disorder (2), tuberculosis (2), and pregnant RSV 
cases (1; 28 years of age) were rare. No RSV case was diagnosed with 
HIV/AIDS (Table 4).
2.8 | Univariable analyses of risk factors for 
RSV and its severe outcomes
In the age-group <5 years, the age-groups 0-5 months and 
6 months-1 year (reference group: 2-4 years); being female; the sea-
sons 2012/13, 2014/15, 2016/17, and 2017/18 (reference season: 
2013/14); and underlying low birth weight, preterm newborn, and 
respiratory and cardiovascular disorder specific to the perinatal 
period were significantly associated with an increased risk of being 
diagnosed with RSV among SARI cases. Underlying congenital mal-
formation of the heart and great vessels, congenital defect originat-
ing in perinatal period, cystic fibrosis, asthma, neurological disorders, 
blood disease, and cancer were significantly associated with a lower 
risk of being diagnosed with RSV. Age-group 0-5 months was signifi-
cantly associated with ICU admission, whereas age-group 2-4 years 
was significantly associated with death among RSV cases. Gender 
and season were not associated with any severe outcomes of RSV. 
Most underlying medical conditions were significantly associated 
with severe outcomes of RSV.
TA B L E  1   ICD-10 codes of underlying medical conditions 
(adapted from Elixhauser and Fleming Comorbidity Indices)
Medical condition ICD-10 code
Disorder of newborn related 
to slow fetal growth and 
fetal malnutrition
P05.-
Extremely low birth weight 
(<1000 g)
P07.0-
Low birth weight 
(1000-2499 g)
P07.1-
Extreme immaturity of 
newborn (<28 weeks)
P07.2
Preterm newborn 
(28-37 weeks)
P07.3
Respiratory and 
cardiovascular disorder 
specific to the perinatal 
period
P20-P29
Congenital malformation of 
the heart
Q20-Q24
Congenital malformation of 
the great vessels
Q25-Q26
Congenital defect 
originating in perinatal 
period
Q02, Q30.-, Q32-Q37, Q44.-, Q60.-, 
Q61.-, P70.0, P70.1, P70.2, P78.8
Down syndrome Q90.-
Sickle-cell disorder D57.-
Cystic fibrosis E84.-
Vitamin D deficiency E55.-
Asthma J45.-, J46
Chronic obstructive 
pulmonary disease (COPD)
J44.-
Chronic pulmonary disease 
(excl. asthma and COPD)
I27.8, I27.9, J40-J43, J47, J60-J67, 
J68.4, J70.1, J70.3
Diabetes E10-E14
Cardiovascular disease A52.0, I05-I08, I09.1, I09.8, I09.9, 
I10, I11, I13, I15, I25.5, I26, I27, 
I28.0, I28.8, I28.9, I34-I39, I42.0, 
I42.5, I42.9, I43, I44.1-I44.3, I45.6, 
I45.9, I47-I50, P29.0, Q23.0-Q23.3, 
R00.0, R00.1, R00.8, T82.1, Z45.0, 
Z95.0, Z95.2, Z95.4
Neurological disorders G10-G13, G20, G22, G25.4, G25.5, 
G31.2, G31.8, G31.9, G32, G35-
G37, G40, G41, G93.1, G93.4, 
R47.0, R56
Blood disease D50.0, D50.8, D50.9, D51-D53, 
D65-D68, D69.1, D69.3-D69.6
Renal failure I12.0, I13.1, N18, N19, N25, Z49.0, 
Z49.2, Z94.0, Z99.2
Liver disease B18, I85, I86, I98, K70, K71.1, 
K71.3, K71.5, K71.7, K72, K74, 
K76.0, K76.2, K76.9, Z94.4
Tuberculosis A15-A19
(Continues)
Medical condition ICD-10 code
Cancer C00-C26, C30-C34, C37-C41, C43, 
C45-C58, C60-C85, C88, C96, 
C90.0, C90.2, C97
HIV/AIDS B20-B22, B24
Pregnancy O00-O99
TA B L E  1   (Continued)
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In the age-group ≥5 years, the age-group 5-64 years; the sea-
sons 2012/13, 2014/15, 2016/17, and 2017/18; and underlying 
congenital defect originating in perinatal period, cystic fibrosis, vi-
tamin D deficiency, asthma, and chronic pulmonary disease were 
significantly associated with an increased risk of being diagnosed 
with RSV among SARI cases. Underlying COPD, cardiovascu-
lar disease, and renal failure were significantly associated with a 
lower risk of being diagnosed with RSV. The age-group ≥65 years 
was associated with death among RSV cases. Gender and season 
were not associated with any severe outcomes of RSV. Some med-
ical conditions were significantly associated with severe outcomes 
of RSV.
2.9 | Multivariable analyses of risk factors for RSV 
in age-group <5 years
Among SARI cases aged <5 years, the age-groups 0-5 months (OR: 
20.29, 95% CI: 18.37-22.41) and 6 months-1 year (OR: 4.59, 95% CI: 
4.16-5.06); being female (male: OR: 0.85, 95% CI: 0.80-0.89); the 
seasons 2012/13 (OR: 1.26, 95% CI: 1.12-1.41), 2014/15 (OR: 1.58, 
95% CI: 1.42-1.74), 2015/16 (OR: 1.14, 95% CI: 1.03-1.26), 2016/17 
(OR: 2.06, 95% CI: 1.88-2.27), and 2017/18 (OR: 1.78, 95% CI: 
1.61-1.97); and underlying respiratory and cardiovascular disorder 
specific to the perinatal period (OR: 1.32, 95% CI: 1.11-1.57) were 
significantly associated with an increased risk of being diagnosed 
F I G U R E  1   Number of SARI cases and 
RSV cases by age-group, week 01/2009-
20/2018
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with RSV. Underlying congenital malformation of the heart (OR: 
0.69, 95% CI: 0.56-0.85) and great vessels (OR: 0.38, 95% CI: 0.26-
0.58), congenital defect originating in perinatal period (OR: 0.41, 
95% CI: 0.31-0.55), asthma (OR: 0.40, 95% CI: 0.30-0.53), neuro-
logical disorders (OR: 0.52, 95% CI: 0.43-0.62), and blood disease 
(OR: 0.60, 95% CI: 0.48-0.75) were significantly associated with a 
lower risk of being diagnosed with RSV (Table 5).
2.9.1 | Multivariable analyses of risk factors for 
severe outcomes of RSV in age-group <5 years
Among RSV cases aged <5 years, the age-group 0-5 months (OR: 
2.39, 95% CI: 1.45-3.94), underlying low birth weight (OR: 6.77. 95% 
CI: 1.28-35.71), preterm newborn (OR: 6.71, 95% CI: 2.19-20.61), 
respiratory and cardiovascular disorder specific to the perinatal pe-
riod (OR: 4.97, 95% CI: 3.36-7.34), congenital malformation of the 
heart (OR: 3.65, 95% CI: 1.90-7.02) and great vessels (OR: 3.50, 95% 
CI: 1.10-11.18), congenital defect origination in perinatal period (OR: 
4.07, 95% CI: 1.71-9.70), cardiovascular disease (OR: 5.19, 95% CI: 
2.77-9.72), neurological disorders (OR: 6.48, 95% CI: 3.76-11.18), 
blood disease (OR: 3.67, 95% CI: 1.98-6.79), and liver disease (OR: 
14.99, 95% CI: 1.49-150.82) were significantly associated with ICU 
admission (Table 5).
Underlying low birth weight (OR: 6.44, 95% CI: 1.56-26.55), 
preterm newborn (OR: 3.91, 95% CI: 1.20-12.81), respiratory and 
cardiovascular disorder specific to the perinatal period (OR: 8.82, 
95% CI: 5.23-14.89), congenital malformation of the heart (OR: 3.85, 
95% CI: 1.63-9.13), congenital defect originating in perinatal period 
TA B L E  2   Number of SARI and RSV cases and proportion of RSV 
cases in SARI cases by age-group, week 01/2009-20/2018
Age-group
SARI case RSV case
n n (%)
0-5 months 11 014 4783 (43)
6 months-1 year 22 207 3213 (14)
2-4 years 15 530 525 (3)
5-64 years 101 668 118 (0.1)
≥65 years 263 133 122 (0.05)
Total 413 552 8761 (2)
TA B L E  3   RSV cases and RSV cases with severe outcomes by gender and age-group (RSV cases and deceased RSV cases: week 01/2009-
20/2018; ICU-admitted RSV cases and ventilated RSV cases: week 01/2013-20/2018 original sentinel hospitals, week 01/2015-20/2018 
additional sentinel hospitals)
Age-group
RSV cases ICU-admitted RSV cases Ventilated RSV cases Deceased RSV cases
Male Female Male Female Male Female Male Female
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
0-5 months 2684 (54) 2099 (55) 164 (63) 164 (71) 61 (60) 53 (63) 0 (0) 3 (19)
6 months-1 year 1875 (38) 1338 (35) 54 (21) 35 (15) 17 (17) 10 (12) 2 (22) 3 (19)
2-4 years 273 (6) 252 (7) 12 (5) 9 (4) 3 (3) 5 (6) 1 (11) 1 (6)
5-64 years 62 (1) 56 (1) 13 (5) 5 (2) 6 (6) 2 (2) 1 (11) 2 (13)
≥65 years 61 (1) 61 (2) 19 (7) 17 (7) 14 (14) 14 (17) 5 (56) 7 (44)
Total 4955 3806 262 230 101 84 9 16
F I G U R E  3   Number of RSV cases and RSV cases with severe outcomes by calendar week, week 01/2015-20/2018
0
20
40
60
80
100
120
140
160
180
200
01
/2
01
5 5 9 13 17 21 25 29 33 37 41 45 49
01
/2
01
6 5 9 13 17 21 25 29 33 37 41 45 49
01
/2
01
7 5 9 13 17 21 25 29 33 37 41 45 49
01
/2
01
8 5 9 13 17
N
um
be
r o
f c
as
es
Calendar week
RSV cases ICU-admied RSV cases Venlated RSV cases Deceased RSV cases
     |  7CAI et Al.
(OR: 3.30, 95% CI: 1.05-10.34), cystic fibrosis (OR: 35.13, 95% CI: 
1.76-700.59), cardiovascular disease (OR: 5.96, 95% CI: 2.71-13.08), 
neurological disorders (OR: 4.43, 95% CI: 2.05-9.56), blood disease 
(OR: 8.22, 95% CI: 4.13-16.36), and liver disease (OR: 13.70, 95% CI: 
1.81-103.80) were significantly associated with application of venti-
lator support (Table 5).
Underlying chronic pulmonary disease (OR: 12.58, 95% CI: 1.13-
140.15), cardiovascular disease (OR: 9.42, 95% CI: 1.46-60.82), neu-
rological disorders (OR: 21.70, 95% CI: 4.98-94.51), blood disease 
(OR: 12.17, 95% CI: 2.23-66.26), and liver disease (OR: 170.86, 95% 
CI: 20.54-1421.11) were significantly associated with an increased 
risk of death (Table 5).
2.10 | Multivariable analyses of risk factors for RSV 
in age-group ≥5 years
Among SARI cases aged ≥5 years, the age-group 5-64 years 
(≥65 years: OR: 0.53, 95% CI: 0.39-0.71); the seasons 2012/13 (OR: 
2.74, 95% CI: 1.38-5.45), 2014/15 (OR: 2.15, 95% CI: 1.12-4.15), 
TA B L E  4   RSV cases and RSV cases with severe outcomes by underlying medical condition (RSV cases and deceased RSV cases: week 
01/2009-20/2018; ICU-admitted RSV cases and ventilated RSV cases: week 01/2013-20/2018 original sentinel hospitals, week 01/2015-
20/2018 additional sentinel hospitals)
 
N (%) of RSV cases
n = 8761
N (%) of ICU-admitted 
RSV cases
n = 492
N (%) of ventilated 
RSV cases
n = 185
N (%) of deceased 
RSV cases
n = 25
Medical condition
Disorder of newborn related to slow fetal 
growth and fetal malnutrition
6 (0.1) 1 (0.2) 0 0
Extremely low birth weight (<1000 g) 9 (0.1) 3 (0.6) 3 (1.6) 0
Low birth weight (1000-2499 g) 51 (0.6) 16 (3.4) 12 (6.5) 0
Extreme immaturity of newborn 
(<28 weeks)
8 (0.1) 3 (0.6) 3 (1.6) 0
Preterm newborn (28-37 weeks) 62 (0.8) 21 (4.4) 14 (7.6) 0
Respiratory and cardiovascular disorder 
specific to the perinatal period
282 (3.5) 60 (12.7) 35 (19.0) 1 (4.0)
Congenital malformation of the heart 131 (1.6) 35 (7.4) 19 (10.3) 2 (8.0)
Congenital malformation of the great 
vessels
34 (0.4) 13 (2.8) 8 (4.4) 0
Congenital defect originating in perinatal 
period
61 (0.7) 14 (2.9) 8 (4.3) 1 (4.0)
Down syndrome 42 (0.5) 9 (1.9) 2 (1.1) 0
Sickle-cell disorder 2 (0.0) 0 0 0
Cystic fibrosis 9 (0.1) 1 (0.2) 1 (0.5) 0
Vitamin D deficiency 13 (0.2) 3 (0.6) 3 (1.6) 1 (4.0)
Asthma 63 (0.7) 4 (0.8) 1 (0.5) 0
Chronic obstructive pulmonary disease 
(COPD)
43 (0.5) 11 (2.2) 8 (4.3) 3 (12.0)
Chronic pulmonary disease (excl. asthma 
and COPD)
54 (0.6) 5 (1.0) 5 (2.7) 2 (8.0)
Diabetes 62 (0.7) 16 (3.3) 12 (6.5) 4 (16.0)
Cardiovascular disease 222 (2.5) 69 (14.0) 47 (25.4) 15 (60.0)
Neurological disorders 167 (1.9) 34 (6.9) 18 (9.7) 8 (32.0)
Blood disease 129 (1.5) 33 (6.7) 25 (13.5) 9 (36.0)
Renal failure 65 (0.7) 22 (4.5) 14 (7.6) 6 (24.0)
Liver disease 24 (0.3) 8 (1.6) 5 (2.7) 5 (20.0)
Tuberculosis 2 (0.0) 1 (0.2) 1 (0.5) 0
Cancer 27 (0.3) 4 (0.8) 2 (1.1) 1 (4.0)
HIV/AIDS 0 0 0 0
Pregnancy 1 (0.0) 0 0 0
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2016/17 (OR: 4.41, 95% CI: 2.43-7.99), and 2017/18 (OR: 8.51, 95% 
CI: 4.78-15.15); and underlying congenital defect originating in peri-
natal period (OR: 3.74, 95% CI: 1.19-11.76), cystic fibrosis (OR: 13.40, 
95% CI: 5.83-30.78), vitamin D deficiency (OR: 2.57, 95% CI: 1.12-
5.93), and chronic pulmonary disease (OR: 2.04, 95% CI: 1.23-3.38) 
were significantly associated with an increased risk of being diag-
nosed with RSV (Table 6).
2.11 | Multivariable analyses of risk factors for 
severe outcomes of RSV in age-group ≥5 years
Among RSV cases aged ≥5 years, underlying blood disease was 
significantly associated with ICU admission (OR: 4.38, 95% CI: 
1.56-12.27), application of ventilator support (OR: 3.40, 95% CI: 
1.22-9.55), and death (OR: 7.17, 95% CI: 1.31-19.15). Underlying 
renal failure (OR: 2.27, 95% CI: 1.13-4.55) was significantly associ-
ated with ICU admission. The age-group ≥65 years (OR: 5.01, 95% 
CI: 1.31-19.15) was significantly associated with an increased risk of 
death (Table 6).
3  | DISCUSSION
The ICOSARI surveillance data enabled us to describe epidemiology 
of hospitalized RSV in Germany and to identify risk factors for being 
diagnosed with RSV and severe outcomes of RSV in hospital. Besides 
the previously known risk factors for RSV and its severe outcomes 
including young age, certain underlying neonatal disorders, and 
chronic pulmonary and cardiovascular diseases, underlying cystic fi-
brosis and vitamin D deficiency were also found to be risk factors for 
being diagnosed with RSV. For severe outcomes of RSV, age-group 
≥65 years, underlying cystic fibrosis, neurological disorders, blood 
disease, liver disease, and renal failure were found to be risk factors.
In our study, the majority of SARI cases were older adults, 
whereas most RSV cases were young children. However, almost 
half of the deceased RSV cases were older adults. The ICU admis-
sion rate among hospitalized RSV cases (2%-19%) and RSV fatality 
rate (0%-5%) vary in different studies.1,12,19-21 Our results are within 
these ranges. In our study, the deceased RSV cases stayed in hospital 
in average longer than other RSV cases. RSV fatality rate was at least 
10 times higher among ICU-admitted and ventilated RSV cases than 
other RSV cases. The number of RSV cases was higher in the season 
2016/17 during the study period which is in line with the finding 
of the RSV surveillance in the United States.22 The majority of RSV 
cases were without the underlying medical conditions in our study. 
However, in most deceased RSV cases, underlying cardiovascular 
disease was present.
The majority of RSV cases were aged <5 years in our study. Thus, 
we investigated risk factors separately in two age-groups <5 and 
≥5 years. To avoid confounding effects, we included in the multi-
variable models variables with significant association with RSV or its 
severe outcomes in the univariable models. 
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In the multivariable models for the age-group <5 years, among 
SARI cases, children in the first months of life were significantly 
more likely to be diagnosed with RSV, and among RSV cases, they 
were more likely to be admitted to ICU. Our findings are concordant 
with the majority of reports that young age is a risk factor for hospi-
talization due to RSV1,2,10 and age below 3 months contributes to the 
increased severity of RSV disease.23 Being male is normally known 
to be a risk factor for RSV.10,24 However, Grimwood et al reported 
non-significant association between being male and RSV.25 In our 
study, being female was a risk factor for being diagnosed with RSV, 
and gender did not play a role in developing severe outcomes of RSV. 
The association between RSV and season varied across the 9 sea-
sons. RSV was more likely to be diagnosed in the seasons 2016/17 
and 2017/18.
Low birth weight and prematurity are widely recognized as 
important risk factors for RSV.8-10 In our study, they were not as-
sociated with being diagnosed with RSV, but were risk factors for 
ICU admission and application of ventilator support in RSV cases. 
Immature immune system, poorly developed airway, and reduced 
respiratory muscle capacity of premature infants may contribute 
to this risk.9,26 Children with underlying congenital heart and great 
vessel disease, congenital defect originating in perinatal period, 
neurological disorders, and blood disease were significantly more 
likely to be diagnosed with other SARI compared to RSV in our 
study. However, the above-mentioned underlying medical con-
ditions, underlying cystic fibrosis, chronic pulmonary disease, 
cardiovascular disease, and liver disease still contributed to the 
severe outcomes among RSV cases. Our findings are in agreement 
TA B L E  6   Multivariable logistic regression analyses of risk factors for RSV and its severe outcomes in age-group ≥5 years (RSV cases and 
deceased RSV cases: week 01/2009-20/2018; ICU-admitted RSV cases and ventilated RSV cases: week 01/2013-20/2018 original sentinel 
hospitals, week 01/2015-20/2018 additional sentinel hospitals)
 
RSV case ICU-admitted RSV case Ventilated RSV case Deceased RSV case
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Age-group
5-64 years (reference 
group)
1      1  
≥65 years 0.53 0.39-0.71     5.01 1.31-19.15
Season
2009/10 0.60 0.17-2.11       
2010/11 1.29 0.52-3.21       
2011/12 1.65 0.73-3.73       
2012/13 2.74 1.38-5.45       
2013/14 (reference group) 1        
2014/15 2.15 1.12-4.15       
2015/16 1.71 0.87-3.39       
2016/17 4.41 2.43-7.99       
2017/18 8.51 4.78-15.15       
Medical condition
Congenital defect 
originating in perinatal 
period
3.74 1.19-11.76       
Cystic fibrosis 13.40 5.83-30.78       
Vitamin D deficiency 2.57 1.12-5.93       
Asthma 1.73 0.96-3.12       
Chronic obstructive 
pulmonary disease 
(COPD)
0.75 0.50-1.11       
Chronic pulmonary 
disease (excl. asthma and 
COPD)
2.04 1.23-3.38       
Cardiovascular disease 0.71 0.53-0.96       
Blood disease   4.38 1.56-12.27 3.40 1.22-9.50 7.17 1.31-19.15
Renal failure 0.77 0.56-1.06 2.27 1.13-4.55     
Note: Statistically significant results appear in bold.
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with the reports that among infants, underlying congenital heart 
disease or lung disease increases severity of hospitalized RSV,27-29 
and RSV infection is more severe in those with underlying cystic 
fibrosis.9,30,31 Poor growth and malnutrition are symptoms of cys-
tic fibrosis which may affect pulmonary function and have an im-
pact on the severity of RSV disease in infants with RSV and cystic 
fibrosis.9,31
In the multivariable models for the age-group ≥5 years, older 
adults were significantly unlikely to be diagnosed with RSV. 
However, they were significantly more likely to have severe out-
come of death if they were diagnosed with RSV. This finding can 
be explained that RSV similar to seasonal influenza can cause se-
vere respiratory complications in older adults, resulting in respira-
tory failure and high mortality.32 Gender was not associated with 
RSV or its severe outcomes. Like the age-group <5 years, RSV was 
more likely to be diagnosed in the seasons 2016/17 and 2017/18. 
Although underlying cystic fibrosis normally increases severity of 
RSV in infants,9,30,31 in our study, it was also a risk factor for being 
diagnosed with RSV in older children and adults. Our results regard-
ing vitamin D deficiency are in line with the findings that vitamin D 
may protect against RSV-associated ALRI since vitamin D may influ-
ence the development of immune system, modulate early lung de-
velopment, and decrease viral load during infection,33 but vitamin 
D deficiency is not associated with the increased severity of RSV.34
Underlying Down syndrome was reported as a risk factor for 
RSV in some studies,10,35 whereas some other studies did not find 
the association.10,20 In our study, it was like underlying disorder of 
newborn related to slow fetal growth and fetal malnutrition, dia-
betes, and cancer not associated with RSV or its severe outcomes 
in both age-groups. The young age is associated with hospitalized 
RSV.1,2,10 However, children with Down syndrome that are admit-
ted to the hospital tend to be older than children with RSV in-
fection.35 This may partly explain our finding regarding the Down 
syndrome. RSV and other respiratory pathogens in early life play 
an important role in the inception and exacerbation of asthma.36,37 
We investigated underlying asthma as a possible risk factor for 
RSV and its severe outcomes. In age-group <5 years, asthma pa-
tients were more likely to be diagnosed with other SARI compared 
to RSV, and in age-group ≥5 years, no associations were found. 
However, RSV may be underdiagnosed in asthma patients due to 
similar clinical presentation, if no fever is present. COPD patients 
may be more susceptible to RSV infection38; however, we found 
no associations. In our study, the number of RSV cases with un-
derlying sickle-cell disorder, tuberculosis, and pregnant RSV cases 
was too low to support the data analyses. Underlying neurological 
disorders, blood disease, liver disease, and renal failure have been 
rarely investigated as possible risk factors for RSV or its severe 
outcomes in the literature. In our study, they contributed to the 
severe outcomes in RSV cases.
Our study has some limitations. Based on the hospitalization 
data alone, information on socio-demographic factors except age 
and gender as well as environmental factors for RSV could not be 
captured. Thus, socio-demographic and environmental factors 
and underlying medical conditions could not be evaluated in one 
model, which limited a comprehensive understanding of the risk 
factors for RSV and its severe outcomes. Further, no data were 
available to identify any children who had received palivizumab 
which would reduce the strength of association with risk fac-
tors. ICOSARI is a ICD-10-based syndromic surveillance system. 
Virological data of the ICOSARI network were not available. As the 
coding behavior of physicians may vary based on use of laboratory 
diagnostics and level of coding awareness, some true cases may be 
missed or wrongly included due to miscoding which could lead to 
information bias. RSV is also a common pathogen of ARI in older 
adults. In our study, among those aged ≥65 years, the proportion 
of RSV cases in SARI cases was lower than that reported in the 
literature.39 Our data suggest that in elderly SARI patients, RSV 
testing might be less frequently carried out. Thus, in our analy-
sis we always use the expression being diagnosed with RSV not 
RSV infection. Also for this reason, we realized that we cannot ex-
clude underdiagnosis of RSV, leading to underestimation of risks. 
Although the sample size of our study population and RSV cases 
was large, the number of deceased RSV cases and RSV cases with 
some underlying medical conditions was small which may lead 
to sparse data bias, especially for the evaluation of risk factors 
for deceased RSV cases and underlying liver disease as risk fac-
tor in age-group <5 years. However, few other studies were large 
enough to look into the risk of death, whereas our approach using 
surveillance data, despite this limitation, allowed analysis of de-
ceased RSV cases.
4  | CONCLUSIONS
Using ICD-10-based surveillance data allows to identify risk factors 
for being diagnosed with RSV and severe outcomes of RSV in hos-
pital, to quantify the risk in different age-groups, and to monitor the 
risk routinely. Our findings will contribute to the development of a 
baseline for evaluating RSV vaccination strategies and RSV vaccina-
tion impact in the future, in particular on the target groups, and help 
reducing burden of RSV disease and its severe outcomes.
Further studies regarding risk factors for RSV are needed with 
the focus on the underlying medical conditions with inconsistent 
findings compared with the literature with consideration of so-
cio-demographic and environmental factors.
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